Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management Strategies

Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management Strategies

In the last few years, monoclonal antibodies (mAbs) such as elotuzumab and daratutumab have brought the treatment of multiple myeloma (MM) into the new era of immunotherapy. More recently, chimeric antigen receptor (CAR) modified T cell, a novel cellular immunotherapy, has been developed for treatme...

Full description

Bibliographic Details
Main Authors: Xiang Zhou, Leo Rasche, K. Martin Kortüm, Sophia Danhof, Michael Hudecek, Hermann Einsele
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-12-01
Series:Frontiers in Immunology
Subjects:
CAR T cell
clinical trial
multiple myeloma
toxicity
pathophysiology
management
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2020.620312/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2020.620312/full

Similar Items